TGF-β/SMAD2/3/4
Principle
SMAD proteins are transcription factors that respond to transforming growth factor-β (TGFβ) signaling, where TGFβ induces its membrane receptors to directly activate Smad proteins. These activated Smads complex with Smad4 (co-Smad), translocate from cytoplasm into nucleus and bind to target promoter region to regulate gene transcriptions. Dysfunction in TGFβ pathway leads to immunosuppression and angiogenesis, which can make cancer more invasive.
Signosis has developed SMAD/TGFβ luciferase reporter stable cell lines by co-transfecting a SMAD luciferase reporter vector and a hygromycin expression vector. The hygromycin resistant clones were subsequently screened for TGFβ1-induced luciferase activity. The cell line can be used as a reporter system for monitoring the activation of SMAD triggered by stimuli treatment, such as TGFβ1 and TGFβ3, and gene overexpression and gene knockdown.
Benefits
High Sensitivity & Responsiveness
Each cell line is validated to induce a strong reporter signal in response to stimuli.
Consistent
TF reporter construct is stably integrated into the genome to avoid experimental/cell-to-cell variations.
Time-Saving
Cell line can be used for experiments right away to study different signaling pathways.
Routine Mycoplasma Testing
All cell lines tested negative for mycoplasma.
